Table of Contents
Table of Contents
Table of Exhibits
Executive Summary
Section 1: Introduction
- Report Scope
- Survey Methodology
Section 2: Disease Dynamics
- NSCLC Background
- Incidence and Drug Treatable Pool
- Major Markets Statistics and Key Findings
- US Statistics and Key Findings
- Europe Statistics and Key Findings
- Japan Statistics and Key Findings
- Prescribers
- Prescriber Trends
- Key Drivers of Prescriber Decisions
- Reimbursement Issues
- Treatment Dynamics
- NSCLC Staging
- Treatment Algorithm
- Existing Therapies
- Emerging Therapies
Section 3: Competitive Analysis
- Overview of Competitive Landscape
- Brand Overview
- Promotional Spending
- Physician Perceptions
- Perceptions of Competitors in NSCLC
- Perceptions of Brands in NSCLC
Section 4: Established Competitors
- Eli Lilly
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Market Strategy
- Outlook
- Alimta
- Current Positioning
- Alimta Competitive Analysis
- Key Brand Strategies
- Future Positioning
- Gemzar
- Current Positioning
- Gemzar Competitive Analysis
- Key Brand Strategies
- Future Positioning
- Roche/Genentech
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Market Strategy
- Outlook
- Tarceva
- Current Positioning
- Tarceva Competitive Analysis
- Key Brand Strategies
- Future Positioning
- Avastin
- Current Positioning
- Avastin Competitive Analysis
- Key Brand Strategies
- Future Positioning
- Sanofi]Aventis
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Market Strategy
- Outlook
- Taxotere
- Current Positioning
- Taxotere Competitive Analysis
- Key Brand Strategies
- Future Positioning
- Bristol]Myers Squibb
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Outlook
- Emerging: Erbitux
- Current Positioning
- Competitive Analysis
- Future Positioning
- AstraZeneca
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Outlook
- Iressa
- Current Positioning
- Future Positioning
- Emerging: Zactima
- Current Positioning
- Future Positioning
- Emerging: Recentin
- Current Positioning
- Future Positioning
Section 5: Emerging Competitors
- Merck Serono
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in NSCLC
- Emerging: Stimuvax
- Current Positioning
- Future Positioning
- Bayer Schering
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in NSCLC
- Emerging: Nexavar
- Current Positioning
- Future Positioning
Section 6: Market Forecast
- NSCLC Market Overview
- Sales by Region
- Sales by Class
- Taxanes
- Antimetabolites
- EGFR Inhibitors
- VEGFR Inhibitors
- Platinum Agents and Other Cytotoxic Agents
- Immunotherapies
Section 7: Appendices
- Abbreviations Used in this Report
- Methodology
- Epidemiology
- Market Forecast
- Emerging Therapy Prices
- Competitive Analysis
Table of Exhibits
Executive Summary
- Exhibit 1: Key Parameters of the NSCLC Market
- Exhibit 2: NSCLC Branded Market, ($US), Major Markets, 2006 - 2011
- Exhibit 3: NSCLC Market Competitive Position, 2006 and 2011
- Exhibit 4: Leading NSCLC Brand Sales, 2006 and 2011
- Exhibit 5: Company Reputations in NSCLC Treatment and Oncology in General
- Exhibit 6: Physician' s Forecasted Changes in Drug Prescribing Patterns
Section 1: Introduction
- Exhibit 7: Surveyed Physicians' Years of Practice
- Exhibit 8: Surveyed Physicians' NSCLC Patients per Month
- Exhibit 9: Surveyed Physicians' Geographic Distribution
Section 2: Disease Dynamics
- Exhibit 10: Anatomy and Histology of NSCLC
- Exhibit 11: Contribution of Risk Factors to Incidence of NSCLC in Major
Pharmaceutical Markets
- Exhibit 12: Existing NSCLC Drugs, by Drug Class
- Exhibit 13: Drug Treatable and Incident NSCLC Cases, Major Markets, 2006 -
2011
- Exhibit 14: Drug Treatable and Incident NSCLC Cases, US, 2006 - 2011
- Exhibit 15: Drug Treatable and Incident NSCLC Cases, Europe
- Exhibit 16: Drug Treatable and Incident NSCLC Cases, Europe, Continued
- Exhibit 17: Drug Treatable and Incident NSCLC Cases, Japan, 2006 - 2011
- Exhibit 18: Preferred Drug Treatment Information Sources for NSCLC
Physicians
- Exhibit 19: Information Sources Used in Previous Three Months by NSCLC
Physicians
- Exhibit 20: Drug Marketing Messages that Positively Influence Physician Use
- Exhibit 21: US Formulary Status of Leading NSCLC Drugs (Non]Medicare
Coverage)
- Exhibit 22: Percentage of US Private Plans Listing Avastin, Erbitux, or
Tarceva as Medical Benefit, Pharmacy Benefit, or Off Formulary
- Exhibit 23: Coinsurance Requirements of US Private Plans for Avastin,
Erbitux, and Tarceva
- Exhibit 24: Coinsurance Requirements of US Medicare Plans for Avastin,
Erbitux, and Tarceva
- Exhibit 25: US Formulary Status of Leading NSCLC Drugs (Medicare Coverage)
- Exhibit 26: Treatment Algorithm for Stage I and II NSCLC
- Exhibit 27: Treatment Algorithm for Stage III and IV NSCLC
- Exhibit 28: Major Treatment Options by NSCLC Stage, Major Markets, 2007
- Exhibit 29: Median Survival Associated with First]Line Treatment of
Advanced]Stage NSCLC
- Exhibit 30: Emerging NSCLC Drugs, by Drug Class
Section 3: Competitive Analysis
- Exhibit 31: Leading Brands and Competitors in the NSCLC Market, 2006 and
2011
- Exhibit 32: NSCLC Market Competitive Position, 2006 and 2011
- Exhibit 33: NSCLC Market ($US), by Company, 2006 - 2011
- Exhibit 34: Approval Specifications for Leading Brands in NSCLC, To ]Date
- Exhibit 35: Maximum Price per Cycle of Leading Brands in NSCLC ($US), 2006
- Exhibit 36: Promotional Spend for NSCLC Therapies, by Company, as a % of
Total, 2006
- Exhibit 37: Promotional Spend for NSCLC Therapies, by Brand, 2006
- Exhibit 38: Physician Preference for Brand Slogans (Blinded)
- Exhibit 39: Top]of]mind Companies in NSCLC Treatment
- Exhibit 40: Company Reputations in NSCLC Treatment and Oncology in General
- Exhibit 41: Physician Rankings of NSCLC Competitors
- Exhibit 42: Physician Rankings of Best Company in NSCLC Therapy
- Exhibit 43: Top Three Most Influential Companies in NSCLC, 2001 - 2006
- Exhibit 44: Top Three Most Influential Companies in NSCLC, 2007 - 2011
- Exhibit 45: Top]of]Mind NSCLC Brands
- Exhibit 46: Forecast Changes in Drug Prescribing Patterns
Section 4: Established Competitors
- Exhibit 47: Summary of Eli Lilly' s Oncology Product Portfolio
- Exhibit 48: Physician Perceptions of Eli Lilly' s NSCLC Research and
Development
- Exhibit 49: Physician Perceptions of Eli Lilly' s NSCLC Clinical Trials
- Exhibit 50: Physician Perceptions of Eli Lilly' s NSCLC Sales and Marketing
- Exhibit 51: Physician Perceptions of Alimta
- Exhibit 52: Ongoing Clinical Trials for Alimta in NSCLC
- Exhibit 53: Ongoing Clinical Trials for Alimta in Other Cancer Indications
- Exhibit 54: Ongoing Clinical Trials for Alimta in Other Cancer
Indications, Continued
- Exhibit 55: Alimta Brand Revenue ($US), by Region, 2006 - 2011
- Exhibit 56: Alimta Brand Revenue ($US), by Country, 2006 - 2011
- Exhibit 57: Physician Perceptions of Gemzar
- Exhibit 58: Ongoing Clinical Trials for Gemzar in NSCLC
- Exhibit 59: Gemzar Brand Revenue ($US), by Region, 2006 - 2011
- Exhibit 60: Gemzar Brand Revenue ($US), by Country, 2006 - 2011
- Exhibit 61: Summary of Roche/Genentech' s Oncology Product Portfolio
- Exhibit 62: Physician Perceptions of the Roche and Genentech Relationship
- Exhibit 63: Physician Perceptions of Genentech' s NSCLC Research and
Development
- Exhibit 64: Physician Perceptions of Genentech' s NSCLC Clinical Trials
- Exhibit 65: Physician Perceptions of Genentech' s NSCLC Sales and Marketing
- Exhibit 66: Physician Perceptions of Tarceva
- Exhibit 67: Ongoing Clinical Trials for Tarceva in NSCLC
- Exhibit 68: Ongoing Clinical Trials for Tarceva in NSCLC, Continued
- Exhibit 69: Ongoing Clinical Trials for Tarceva in Other Cancer Indications
- Exhibit 70: Tarceva Brand Revenue ($US), by Region, 2006 - 2011
- Exhibit 71: Tarceva Brand Revenue ($US), by Country, 2006 - 2011
- Exhibit 72: Physician Perceptions of Avastin
- Exhibit 73: Roche/Genentech' s Development Program for Avastin
- Exhibit 74: Avastin Brand Revenue ($US), by Region, 2006 - 2011
- Exhibit 75: Avastin Brand Revenue ($US), by Country, 2006 - 2011
- Exhibit 76: Summary of Sanofi]Aventis' Oncology Product Portfolio
- Exhibit 77: Physician Perceptions of Sanofi]Aventis' NSCLC Research and
Development
- Exhibit 78: Physician Perceptions of Sanofi]Aventis' NSCLC Clinical Trials
- Exhibit 79: Physician Perceptions of Sanofi]Aventis' NSCLC Sales and
Marketing
- Exhibit 80: Physician Perceptions of Taxotere
- Exhibit 81: Ongoing Clinical Trials for Taxotere in NSCLC
- Exhibit 82: Ongoing Clinical Trials for Taxotere in Breast Cancer
- Exhibit 83: Ongoing Clinical Trials for Taxotere in Prostate Cancer
- Exhibit 84: Ongoing Clinical Trials for Taxotere in Other Cancer
Indications
- Exhibit 85: Taxotere Brand Revenue ($US), by Region, 2006 - 2011
- Exhibit 86: Taxotere Brand Revenue ($US), by Country, 2006 - 2011
- Exhibit 87: Summary of BMS' Oncology Product Portfolio
- Exhibit 88: Physician Perceptions of BMS in NSCLC Research and Development
- Exhibit 89: Physician Perceptions of BMS' NSCLC Clinical Trials
- Exhibit 90: Physician Perceptions of BMS' NSCLC Sales and Marketing
- Exhibit 91: Expected Erbitux Revenue ($US), by Region, 2006 - 2011
- Exhibit 92: Expected Erbitux Revenue ($US), by Country, 2008 - 2011
- Exhibit 93: Erbitux' s Expected Price per Cycle
- Exhibit 94: Summary of AstraZeneca' s Oncology Product Portfolio
- Exhibit 95: Physician Perceptions of AstraZeneca in NSCLC Research and
Development
- Exhibit 96: Physician Perceptions of AstraZeneca' s NSCLC Clinical Trials
- Exhibit 97: Physician Perceptions of AstraZeneca' s NSCLC Sales and
Marketing
- Exhibit 98: Iressa Brand Revenue ($US), by Region, 2006 - 2011
- Exhibit 99: Iressa Brand Revenue ($US), by Country, 2006 - 2011
- Exhibit 100: Expected Zactima Revenue ($US), by Region, 2010 - 2011
- Exhibit 101: Expected Zactima Revenue ($US), by Country, 2010 - 2011
- Exhibit 102: Zactima' s Expected Price per Cycle
- Exhibit 103: Expected Recentin Revenue ($US), by Country, 2011
Section 5: Emerging Competitors
- Exhibit 104: Summary of Merck Serono' s Oncology Product Portfolio
- Exhibit 105: Physician Perceptions of Cancer Vaccines
- Exhibit 106: Expected Stimuvax Revenue ($US), by Region, 2010 - 2011
- Exhibit 107: Expected Stimuvax Revenue ($US), by Country, 2010 - 2011
- Exhibit 108: Stimuvax' Expected Price per Cycle
- Exhibit 109: Summary of Bayer Schering' s Oncology Product Portfolio
- Exhibit 110: Expected Nexavar Revenue ($US), by Region, 2009 - 2011
- Exhibit 111: Expected Nexavar Revenue ($US), by Country, 2009 - 2011
- Exhibit 112: Nexavar' s Expected Price per Cycle
Section 6: Market Forecast
- Exhibit 113: NSCLC Market ($US), Major Markets, 2006 - 2011 (Tabular
Format)
- Exhibit 114: NSCLC Market ($US), Major Markets, 2006 - 2011 (Graphical
Format)
- Exhibit 115: Timeline of Key Events, NSCLC Market, 2006 - 2011
- Exhibit 116: NSCLC Market ($US), by Country, 2006 - 2011
- Exhibit 117: NSCLC Market ($US), by Drug Class, 2006 - 2011
- Exhibit 118: NSCLC Market, by Drug Class, as a % of Total, 2006 and 2011
- Exhibit 119: Taxane Market ($US), by Drug, 2006 - 2011
- Exhibit 120: Taxane Market ($US), by Country, 2006 - 2011
- Exhibit 121: Antimetabolite Market ($US), by Drug, 2006 - 2011
- Exhibit 122: Antimetabolite Market ($US), by Country, 2006 - 2011
- Exhibit 123: EGFR Inhibitor Market ($US), by Drug, 2006 - 2011
- Exhibit 124: EGFR Inhibitor Market ($US), by Country, 2006 - 2011
- Exhibit 125: VEGFR Inhibitor Market ($US), by Drug, 2006 - 2011
- Exhibit 126: VEGFR Inhibitor Market ($US), by Country, 2006 - 2011
- Exhibit 127: Platinum Agent Market ($US), by Drug, 2006 - 2011
- Exhibit 128: Platinum Agent Market ($US), by Country, 2006 - 2011
Section 7: Appendices
- Exhibit 129: Discount Prices
- Exhibit 130: Dosing Assumptions for NSCLC Regimens
|
Related Report
|
View Cart
